OTCMLTUS
Market cap111kUSD
Dec 23, Last price
0.00USD
1D
21.97%
1Q
38.79%
Jan 2017
82.95%
IPO
-86.58%
Name
Lotus Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
118.59%
Rev. gr., 5y
%
Revenues
0k
Net income
-19k
L-10.88%
CFO
-19k
L-19.67%
Profile
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | (168) | (228) | (237) | ||
Tax Rate | |||||
NOPAT | 168 | 228 | 237 | ||
Net income | (19) -10.88% | (21) -30.60% | (30) 384.05% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 117 | 97 | 76 | ||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | 115 | 96 | 68 | ||
| Cash flow | |||||
Cash from operating activities | (19) | (24) | (30) | ||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | 20 | 17 | 36 | ||
FCF | 168 | 225 | 237 | ||
| Balance | |||||
Cash | 2 | 1 | 8 | ||
Long term investments | |||||
Excess cash | 2 | 1 | 8 | ||
Stockholders' equity | (30,099) | (32,774) | (29,806) | ||
Invested Capital | 30,105 | 32,779 | 29,814 | ||
ROIC | 0.53% | 0.73% | 0.79% | ||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 2,694,516 | 2,694,516 | 2,944,516 | ||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||